Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.
What happened
FDA inspected Suretec's Gilbert, Arizona drug manufacturing facility from March 2 to 5, 2026, and found significant violations of current good manufacturing practice (CGMP), the quality rules for drug manufacturing, in component testing, microbiological testing, investigations, and quality-unit oversight. FDA also reviewed the firm's drug listing submissions in its electronic Drug Registration and Listing System and found it had not listed KleenLine Alcohol-Free Sanitizing Wipes, which it makes for another company, Brady Industries, that sells it under its own brand. The letter also says the listing for Hand Sanitizing Alcohol-Free Wipes, NDC 84111-000, bears what appears to be another such company's trade name.
What FDA found
Suretec did not test each incoming component, including the active ingredient, for identity and other specifications, and it relied on supplier test certificates without establishing their reliability.
21 CFR 211.84(d)(1) and 211.84(d)(2)Suretec did not adequately test each finished drug batch for harmful microorganisms; its own test method lacked proper incubation times, method suitability, controls and validation.
21 CFR 211.165(b)Suretec did not thoroughly investigate microbial counts over the limit in a component system and used that component to make and release drug products.
21 CFR 211.192Suretec's quality control unit did not ensure adequate written production procedures, stability testing, quality-unit procedures and enough qualified personnel.
21 CFR 211.22; 21 CFR 211.100(a); 21 CFR 211.166(a); 21 CFR 211.22(d); 21 CFR 211.25(c)Suretec made KleenLine Alcohol-Free Sanitizing Wipes for Brady Industries, a company that sells it under its own brand, but did not list the drug under Brady's trade name and labeler code.
Section 510(j) of the FD&C Act, 21 U.S.C. 360(j); 21 CFR 207.41(c)(1)
What FDA wants
FDA asks Suretec to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence, and if it cannot complete the actions in that time, to state why and give a completion schedule. FDA also asks for comprehensive reviews and corrective action plans for the material system, microbiological testing, investigations and the quality unit, plus retain-sample testing and a risk assessment for distributed lots.
Who should pay attention
- brands and private label distributors that buy OTC sanitizing wipes from this contract manufacturer
- retailers that sell alcohol-free sanitizing wipes
- quality teams at contract manufacturers that rely on supplier test certificates
This is a summary. Read the original letter on fda.gov.